Abstract:. In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of ...
1McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Cancer Res (2026) 86 (7_Supplement): 5811.
Abstract. Antibody-drug conjugates (ADCs) enable the specific targeting of a potent cytotoxic drug to cancer cells expressing a select antigen via the release of the cytotoxin covalently linked to a ...
Search for other works by this author on: ...
Search for other works by this author on: ...
School of Pharmaceutical Sciences - USM, Penang, Malaysia.
Search for other works by this author on: ...
Abstract. Breast cancers with high expression of estrogen receptor (ER), progesterone receptor (PR), or Human Epidermal Growth Factor Receptor 2 (HER2) have benefited dramatically from ...
Robert Bosch Centre for Tumor Diseases, Stuttgart, Germany.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results